These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 36192243

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
    Ming J, Wu Y, Han R, Xu X, Waldeck R, Hu S.
    Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
    [Abstract] [Full Text] [Related]

  • 6. Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management.
    Tartarone A, Lerose R, Tartarone M.
    Med Oncol; 2022 May 13; 39(7):107. PubMed ID: 35553247
    [Abstract] [Full Text] [Related]

  • 7. Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide.
    Fujmoto S, Fujita K, Nishimoto M, Hamaguchi M, Kuwahara K, Hashimoto M, Adomi S, Minami T, Nozawa M, Yoshimura K, Uemura H.
    Cancer Med; 2023 Feb 13; 12(3):3176-3179. PubMed ID: 36043427
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
    Appukkuttan S, Farej R, Miles L, Purser M, Wen L.
    J Manag Care Spec Pharm; 2021 Feb 13; 27(2):166-174. PubMed ID: 33141615
    [Abstract] [Full Text] [Related]

  • 11. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors.
    Saad F, Bögemann M, Suzuki K, Shore N.
    Prostate Cancer Prostatic Dis; 2021 Jun 13; 24(2):323-334. PubMed ID: 33558665
    [Abstract] [Full Text] [Related]

  • 12. A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer.
    Hird AE, Magee DE, Bhindi B, Ye XY, Chandrasekar T, Goldberg H, Klotz L, Fleshner N, Satkunasivam R, Klaassen Z, Wallis CJD.
    Clin Genitourin Cancer; 2020 Oct 13; 18(5):343-350. PubMed ID: 32278840
    [Abstract] [Full Text] [Related]

  • 13. Managing Nonmetastatic Castration-resistant Prostate Cancer.
    Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS.
    Eur Urol; 2019 Feb 13; 75(2):285-293. PubMed ID: 30119985
    [Abstract] [Full Text] [Related]

  • 14. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
    Esther J, Maughan BL, Anderson N, Agarwal N, Hahn AW.
    Curr Treat Options Oncol; 2019 Feb 11; 20(2):14. PubMed ID: 30741354
    [Abstract] [Full Text] [Related]

  • 15. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI.
    Prostate Cancer Prostatic Dis; 2022 Feb 11; 25(2):139-148. PubMed ID: 34054128
    [Abstract] [Full Text] [Related]

  • 16. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.
    Hussain A, Jiang S, Varghese D, Appukkuttan S, Kebede N, Gnanasakthy K, Macahilig C, Waldeck R, Corman S.
    BMC Cancer; 2022 Mar 22; 22(1):304. PubMed ID: 35317768
    [Abstract] [Full Text] [Related]

  • 17. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
    Chowdhury S, Oudard S, Uemura H, Joniau S, Dearden L, Capone C, Van Sanden S, Diels J, Hadaschik BA.
    Adv Ther; 2022 Jan 22; 39(1):518-531. PubMed ID: 34797506
    [Abstract] [Full Text] [Related]

  • 18. Novel Androgen Receptor Inhibitors in Non-Metastatic, Castration-Resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis.
    Mulati Y, Fan Y, Yu W, Zhang Q, He Z.
    Front Oncol; 2021 Jan 22; 11():733202. PubMed ID: 34722276
    [Abstract] [Full Text] [Related]

  • 19. Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide.
    Wallis CJD, Chandrasekar T, Goldberg H, Klotz L, Fleshner N, Satkunasivam R, Klaassen Z.
    Eur Urol Oncol; 2018 Aug 22; 1(3):238-241. PubMed ID: 31102627
    [Abstract] [Full Text] [Related]

  • 20. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.
    Cattrini C, Caffo O, De Giorgi U, Mennitto A, Gennari A, Olmos D, Castro E.
    Cancers (Basel); 2022 Mar 31; 14(7):. PubMed ID: 35406564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.